NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

It’s not actually a pricey drug. The cost of treatment looks like it will be quite a lot less if you measure it by month and also the fact that it has virtually no side-effects, can be given in a community setting and extends life. In fact, it probably could justify premium pricing more than what is anticipated, if they asked for it, based on the survival results and based on the poly-iclc results especially.

And if they give them a broad brain cancer label, it’s actually a pretty decent size but they can still get a substantial revenue upon which to base a substantial increase in value even on the UK alone.

But more importantly, the U.K.’s decision will likely provide approval in their treaty and commonwealth countries, including Canada, but a variety of other nations and as well would likely be a good predictor of approvals in the US and EU.

You’ve got drugs that cost almost a million in treatment costs with deaths and serious side-effects that are already approved for a variety of cancers, and yes, those post problems, including CAR-T and Keytruda, with it’s side-effects and relatively high cost over time. You have Optune which is many times more expensive.

So in comparison, the cost of DCVax-L, plus it’s actual increase in mOS and long-tail survivors as well as for subgroups of patients and recurrent patients is a game changer not just in results but in terms of REDUCING costs compared to other “cutting edge” options already approved for other and cancers and for GBM, but also in terms of life extension and allowing a good number of patients to resume their regular lives, some for an extended time, others indefinitely.